Inhaled ciclosporin: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| Line 24: | Line 24: | ||
{{stub}} | {{stub}} | ||
{{No image}} | |||
Revision as of 01:55, 11 February 2025
Inhaled Ciclosporin is a form of the immunosuppressive medication Ciclosporin, which is administered via inhalation. It is currently being researched for its potential use in the prevention of lung transplant rejection and treatment of bronchiolitis obliterans syndrome.
Mechanism of Action
Inhaled Ciclosporin works by inhibiting the activity of calcineurin, a protein that plays a crucial role in the activation of T cells. By doing so, it suppresses the immune system and prevents the body from rejecting a transplanted organ.
Uses
Inhaled Ciclosporin is primarily being studied for its potential use in preventing lung transplant rejection. It is also being researched for its potential use in treating bronchiolitis obliterans syndrome, a severe lung disease that can occur after lung transplantation.
Side Effects
The side effects of Inhaled Ciclosporin are not yet fully known, as it is still in the research phase. However, the oral and intravenous forms of Ciclosporin have been associated with a number of side effects, including kidney damage, high blood pressure, and an increased risk of infection.
Research
Research into Inhaled Ciclosporin is ongoing. Early studies suggest that it may be effective in preventing lung transplant rejection and treating bronchiolitis obliterans syndrome, but more research is needed to confirm these findings and to fully understand the drug's safety profile.


